Patents by Inventor Napoleone Ferrara

Napoleone Ferrara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Secreted and transmembrane polypeptides and nucleic acids encoding the same
    Publication number: 20090170158
    Abstract: The present invention is directed to secreted and transmembrane polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Application
    Filed: March 25, 2008
    Publication date: July 2, 2009
    Inventors: Kevin P. Baker, David Botstein, Dan L. Eaton, Napoleone Ferrara, Ellen Filvaroff, Mary E. Gerritsen, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, Kenneth J. Hillan, Ivar J. Kljavin, Mary A. Napier, Margaret Ann Roy, Daniel Tumas, William I. Wood
  • VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS
    Publication number: 20090169556
    Abstract: The present invention provides human vascular endothelial cell growth factor (hVEGF) antagonists, including monoclonal antibodies, hVEGF receptors, and hVEGF variants that are useful for the treatment of age-related macular degeneration, and other diseases and disorders characterized by undesirable or excessive neovascularization.
    Type: Application
    Filed: March 10, 2009
    Publication date: July 2, 2009
    Applicant: Genentech, Inc.
    Inventors: Napoleone Ferrara, Kyung Jin Kim
  • Secreted and transmembrane polypeptides and nucleic acids encoding the same
    Publication number: 20090142800
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Application
    Filed: November 18, 2005
    Publication date: June 4, 2009
    Inventors: David Botstein, Luc Desnoyers, Napoleone Ferrara, Sherman Fong, Wei-Qiang Gao, Audrey Goddard, Austin L. Gurney, James Pan, Margaret Ann Roy, Timothy A. Stewart, Daniel Tumas, Colin K. Watanabe, William I. Wood
  • Humanized anti-TGF-beta antibodies
    Patent number: 7527791
    Abstract: Humanized anti-TGF-beta antibodies are provided, as well as methods for their preparation and use, including methods for treating TGF-beta disorders, for example, cancer. Also provided are articles of manufacture designed for various uses that contain the humanized antibodies.
    Type: Grant
    Filed: March 31, 2005
    Date of Patent: May 5, 2009
    Assignee: Genentech, Inc.
    Inventors: Camellia W. Adams, Napoleone Ferrara, Ellen H. Filvaroff, Weiguang Mao, Leonard G. Presta, Max L. Tejada
  • COMPOSITION COMPRISING AND METHOD OF USING ANGIOPOIETIN-LIKE PROTEIN 3 ANGPTL3
    Publication number: 20090098117
    Abstract: The present invention is directed to methods and means for making and using Angptl3 polypeptides. The invention specifically concerns the use of Angptl3 polypeptides in inducing liver regeneration and angiogenesis. Further methods include the use of Angptl3 polypeptides in the diagnosis and treatment of liver disease. Also provided herein are antibodies which bind to the polypeptides of the present invention.
    Type: Application
    Filed: May 28, 2008
    Publication date: April 16, 2009
    Inventors: Napoleone FERRARA, Hans-Peter Gerber, Joe Kowalski, Maria Teresa Pisabarro, Daniel Eric Sherman
  • Polypeptides homologous to VEGF and BMP1
    Patent number: 7494977
    Abstract: The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be useful in wound repair, as well as in the generation and regeneration of tissue.
    Type: Grant
    Filed: June 4, 2004
    Date of Patent: February 24, 2009
    Assignee: Genentech, Inc.
    Inventors: Napoleone Ferrara, Sophia S Kuo
  • POLYPEPTIDES HOMOLOGOUS TO VEGF AND BMP1
    Publication number: 20090012003
    Abstract: The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be useful in wound repair, as well as in the generation and regeneration of tissue.
    Type: Application
    Filed: August 8, 2008
    Publication date: January 8, 2009
    Applicant: Genentech, Inc.
    Inventors: Napoleone Ferrara, Sophia S. Kuo
  • METHODS FOR USING CHIMERIC VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR PROTEINS
    Publication number: 20090010933
    Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and anglogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.
    Type: Application
    Filed: April 17, 2008
    Publication date: January 8, 2009
    Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara
  • Secreted and transmembrane polypeptides and nucleic acids encoding the same
    Patent number: 7470771
    Abstract: The present invention is directed to secreted and transmembrane polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: October 2, 2003
    Date of Patent: December 30, 2008
    Assignee: Genentech, Inc.
    Inventors: Kevin P. Baker, David Botstein, Dan L. Eaton, Napoleone Ferrara, Ellen Filvaroff, Mary E. Gerritsen, Audrey Goddard, Paul J. Godowski, Austin L. Gurney, Kenneth J. Hillan, Ivar J. Kijavin, Mary A. Napier, Margaret Ann Roy, Daniel Tumas, William I. Wood
  • VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20080311118
    Abstract: The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF antibodies and VEGF receptor fusion proteins. Methods of treating edema and stroke using VEGF antagonists are also provided.
    Type: Application
    Filed: April 25, 2008
    Publication date: December 18, 2008
    Applicant: Genentech, Inc.
    Inventors: Nicholas Van Bruggen, Napoleone Ferrara
  • Vascular Endothelial Cell Growth Factor Antagonists and Uses Thereof
    Publication number: 20080299116
    Abstract: The present invention provides vascular endothelial cell growth factor (VEGF) antagonists and methods of using VEGF antagonists. VEGF antagonists contemplated by the invention include VEGF antibodies and VEGF receptor fusion proteins. Methods of treating edema and stroke using VEGF antagonists are also provided.
    Type: Application
    Filed: April 21, 2008
    Publication date: December 4, 2008
    Applicant: Genentech, Inc.
    Inventors: Nicholas Van Bruggen, Napoleone Ferrara
  • POLYPEPTIDES HOMOLOGOUS TO VEGF AND BMP1
    Publication number: 20080299119
    Abstract: The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be useful in wound repair, as well as in the generation and regeneration of tissue.
    Type: Application
    Filed: June 26, 2008
    Publication date: December 4, 2008
    Applicant: Genentech, Inc.
    Inventors: Napoleone Ferrara, Sophia S. Kuo
  • PRO211 polypeptides
    Patent number: 7449551
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: February 15, 2006
    Date of Patent: November 11, 2008
    Assignee: Genentech, Inc.
    Inventors: Audrey Goddard, Austin L. Gurney, Paul J. Godowski, William I. Wood, Napoleone Ferrara
  • EG-VEGF nucleic acids and polypeptides and methods of use
    Patent number: 7446168
    Abstract: The present invention is directed to novel polypeptides designated herein as EG-VEGF and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Also provided herein are methods of screening for modulators of EG-VEGF. Furthermore, methods and related methods of treatment are described herein which pertain to regulating cellular proliferation and chemotaxis.
    Type: Grant
    Filed: October 22, 2003
    Date of Patent: November 4, 2008
    Assignee: Genentech, Inc.
    Inventors: Napoleone Ferrara, Colin Watanabe, William I. Wood
  • VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
    Publication number: 20080248033
    Abstract: Disclosed herein are methods of treating benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating a subject at risk of developing benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating or preventing recurrence of a tumor using an anti-VEGF-specific antagonist as well as use of VEGF-specific antagonists in neoadjuvant and adjuvant cancer therapy.
    Type: Application
    Filed: December 18, 2007
    Publication date: October 9, 2008
    Applicant: Genentech, Inc.
    Inventors: Napoleone Ferrara, Nina Korsisaari, Robert D. Mass
  • Variants of vascular endothelial cell growth factor, their uses, and processes for their production
    Patent number: 7427596
    Abstract: The present invention involves the preparation of vascular endothelial growth factor (VEGF) variants which provide materials that are selective in respect of binding characteristics to the kinase domain region and the FMS-like tyrosine-kinase region, respectively KDR and FLT-1. The respective KDR and FLT-1 receptors are bound by corresponding domains within the VEGF compound domains. The variants hereof define those two binding regions and modify them so as to introduce changes that interrupt the binding to the respective domain. In this fashion the final biological characteristics of the VEGF molecule are selectively modified.
    Type: Grant
    Filed: June 3, 2005
    Date of Patent: September 23, 2008
    Assignee: Genentech, Inc.
    Inventors: Bruce A. Keyt, Francis Hung Nguyen, Napoleone Ferrara
  • Methods for Treating Kidney Disorders
    Publication number: 20080206243
    Abstract: Provided are methods of treating kidney disorders in a subject by administering an effective amount of VEGFR agonist, e.g., a Flt1 agonist to a subject. The agonists are composed of compositions comprising VEGFR agonists, e.g., VEGF, antibodies directed to Flt1, Flt1 ligands, Flt1 small molecule activators, or Flt1 selective agents in a pharmaceutically acceptable carrier for use in activating Flt1.
    Type: Application
    Filed: April 25, 2008
    Publication date: August 28, 2008
    Applicant: Genentech, Inc.
    Inventors: Megan Baldwin, Hans-Peter Gerber, Napoleone Ferrara
  • Angiogenesis using hepatocyte growth factor
    Publication number: 20080200375
    Abstract: Methods for enhancing angiogenesis in a mammal using hepatocyte growth factor (“HGF”) are provided. In the methods, HGF can be administered to mammals suffering from, for instance, vascular insufficiency or arterial occlusive disease. Articles of manufacture and kits containing HGF are also provided.
    Type: Application
    Filed: May 25, 2006
    Publication date: August 21, 2008
    Applicants: St. Elizabeth's Medical Center of Boston, Inc.
    Inventors: Napoleone Ferrara, Jeffrey M. Isner, Ralph H. Schwall
  • Secreted and transmembrane polypeptides and nucleic acids encoding the same
    Publication number: 20080182275
    Abstract: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Application
    Filed: April 10, 2007
    Publication date: July 31, 2008
    Inventors: Avi J Ashkenazi, Kevin P. Baker, David Botstein, Luc Desnoyers, Dan L. Eaton, Napoleone Ferrara, Ellen Filvaroff, Sherman Fong, Wei-Qiang Gao, Hanspeter Gerber, Mary E. Gerritsen, Audrey Goddard, Paul J. Godowski, J. Christopher Grimaldi, Austin L. Gurney, Kenneth J. Hillan, Ivar J. Kljavin, Sophia S. Kuo, Mary A. Napier, James Pan, Nicholas F. Paoni, Margaret Ann Roy, David L. Shelton, Timothy A. Stewart, Daniel Tumas, P. Mickey Williams, William I. Wood
  • Vascular Endothelial Cell Growth Factor Antagonists
    Publication number: 20080181900
    Abstract: The present invention provides human vascular endothelial cell growth factor (hVEGF) antagonists, including monoclonal antibodies, hVEGF receptors, and hVEGF variants that are useful for the treatment of age-related macular degeneration, and other diseases and disorders characterized by undesirable or excessive neovascularization.
    Type: Application
    Filed: March 20, 2008
    Publication date: July 31, 2008
    Applicant: Genentech, Inc.
    Inventors: Napoleone Ferrara, Kyung Jin KIM